Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fraser

Showing results (591-600 of 598) with videos related to

Pageof 60
Sort By:
You have reached the last page of results.This site can display upto 598 results.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
Nature Cancer|December 30, 2022
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasisSusana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
JAMA Oncology|July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial, Douglas Yee, Angela M DeMichele, et al.
NPJ Breast Cancer|May 16, 2020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerZuzana Kos, Elvire Roblin, Rim S Kim, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 60

Showing results (591-600 of 598) with videos related to

Sort By:
Pageof 60
You have reached the last page of results.This site can display upto 598 results.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
Nature Cancer|December 30, 2022
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasisSusana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
JAMA Oncology|July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial, Douglas Yee, Angela M DeMichele, et al.
NPJ Breast Cancer|May 16, 2020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerZuzana Kos, Elvire Roblin, Rim S Kim, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 60